WO2008093009A2 - Procédé de préparation de bactériophages modifiés par insertion de séquences aléatoires dans les protéines de ciblage desdits bactériophages - Google Patents

Procédé de préparation de bactériophages modifiés par insertion de séquences aléatoires dans les protéines de ciblage desdits bactériophages Download PDF

Info

Publication number
WO2008093009A2
WO2008093009A2 PCT/FR2007/002101 FR2007002101W WO2008093009A2 WO 2008093009 A2 WO2008093009 A2 WO 2008093009A2 FR 2007002101 W FR2007002101 W FR 2007002101W WO 2008093009 A2 WO2008093009 A2 WO 2008093009A2
Authority
WO
WIPO (PCT)
Prior art keywords
bacteriophage
bacteriophages
protein
targeting
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2007/002101
Other languages
English (en)
French (fr)
Other versions
WO2008093009A8 (fr
WO2008093009A3 (fr
Inventor
François IRIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phaxiam Therapeutics SA
Original Assignee
Pherecydes Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pherecydes Pharma SA filed Critical Pherecydes Pharma SA
Priority to JP2009542133A priority Critical patent/JP2010512774A/ja
Priority to US12/520,789 priority patent/US9315803B2/en
Priority to EP07872388A priority patent/EP2097516B1/fr
Priority to AU2007346006A priority patent/AU2007346006B2/en
Priority to CA2673579A priority patent/CA2673579C/fr
Publication of WO2008093009A2 publication Critical patent/WO2008093009A2/fr
Publication of WO2008093009A3 publication Critical patent/WO2008093009A3/fr
Anticipated expiration legal-status Critical
Publication of WO2008093009A8 publication Critical patent/WO2008093009A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae

Definitions

  • Bacteriophages are viruses that can specifically infect and replicate bacteria. Their existence has been demonstrated at the beginning of XX th century by the British Frederick Twort and Felix d'Hérelle Quebecers.
  • bacteriophages are taken from the wild or from collections, to form together what is called a "cocktail of bacteriophages".
  • bacteriophages are taken from the wild or from collections, to form together what is called a "cocktail of bacteriophages".
  • This method is designed to be implemented with a minimum of replication cycle in the host bacterium, see only one.
  • This reconstitution can be carried out in a conventional manner by reconstitution of a modified copy of the gene or a part of this gene by cloning, that is to say by assembling the oligonucleotides randomly produced to conserved segments of the sequence. in a vector. Nevertheless, this step can prove to be very tedious, because of subcloning and many verification steps that this may involve.
  • PCR-error is meant a chain polymerization reaction carried out under conditions that do not allow faithful replication of the DNA sequences.
  • This type of reaction can be obtained by using a conventional Taq-type polymerase under weakly stringent conditions and in the presence of manganese salts, as described in the literature [Cadwell, RC et al., Randomization of genes by PCR mutagenesis, PCR Methods Appl., 1992, 28-33].
  • a faithful PCR is, on the contrary, a chain polymerization reaction for amplifying a DNA template with a very low replication error rate.
  • This type of reaction can be obtained by using, for example, a Pfu polymerase under stringent conditions, as described in the literature [Inmis, MA and Eds., PCR Protocols: a guide to methods and applications, 1989, Academy Press].
  • DNA constructs according to the invention taken as a whole, make it possible to integrate into the genome of the bacteriophage a very large number of different nucleotide sequences encoding modified targeting proteins.
  • the bacteriophage comprises a capsid protein fused to a luminescent or fluorescent protein such as, for example, GFP (Green Fluorescent Protein).
  • a luminescent or fluorescent protein such as, for example, GFP (Green Fluorescent Protein).
  • Another subject of the invention relates to a solid or liquid composition
  • a solid or liquid composition comprising a bacteriophage library according to the invention, for example a powder that can be sprayed on a surface that is to be made free of bacteria.
  • extension protocol can be modified as follows:
  • the final fused PCR product (gp12BD-Fu) is purified by gel electrophoresis since its dimensions are very different from those of the individual matrices.
  • a fresh night culture of DK8-T4Mut- ⁇ cells is prepared in LB + ChI + Kan + Amp medium at 30 ° C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
PCT/FR2007/002101 2006-12-20 2007-12-18 Procédé de préparation de bactériophages modifiés par insertion de séquences aléatoires dans les protéines de ciblage desdits bactériophages Ceased WO2008093009A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2009542133A JP2010512774A (ja) 2006-12-20 2007-12-18 バクテリオファージのスクリーニング蛋白質へのランダム配列挿入により改変されたバクテリオファージの作製方法
US12/520,789 US9315803B2 (en) 2006-12-20 2007-12-18 Method for the preparation of modified bacteriophages by insertion of random sequences in the targeting proteins of said bacteriophages
EP07872388A EP2097516B1 (fr) 2006-12-20 2007-12-18 Procédé de préparation de bactériophages modifiés par insertion de séquences aléatoires dans les protéines de ciblage desdits bactériophages
AU2007346006A AU2007346006B2 (en) 2006-12-20 2007-12-18 Method for the preparation of modified bacteriophages by insertion of random sequences in the targeting proteins of said bacteriophages
CA2673579A CA2673579C (fr) 2006-12-20 2007-12-18 Procede de preparation de bacteriophages modifies par insertion de sequences aleatoires dans les proteines de ciblage desdits bacteriophages

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0655721 2006-12-20
FR0655721A FR2910492B1 (fr) 2006-12-20 2006-12-20 Procede de preparation de bacteriophages modifies par insertion de sequences aleatoires dans les proteines de ciblage desdits bacteriophages

Publications (3)

Publication Number Publication Date
WO2008093009A2 true WO2008093009A2 (fr) 2008-08-07
WO2008093009A3 WO2008093009A3 (fr) 2009-02-12
WO2008093009A8 WO2008093009A8 (fr) 2009-07-16

Family

ID=38293109

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/002101 Ceased WO2008093009A2 (fr) 2006-12-20 2007-12-18 Procédé de préparation de bactériophages modifiés par insertion de séquences aléatoires dans les protéines de ciblage desdits bactériophages

Country Status (7)

Country Link
US (1) US9315803B2 (https=)
EP (2) EP2653536A1 (https=)
JP (1) JP2010512774A (https=)
AU (1) AU2007346006B2 (https=)
CA (1) CA2673579C (https=)
FR (1) FR2910492B1 (https=)
WO (1) WO2008093009A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010125296A1 (fr) 2009-04-30 2010-11-04 Pherecydes Pharma Modification du genome d'un bacteriophage lytique par immobilisation dudit bacteriophage dans sa bacterie hote

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017174809A1 (en) * 2016-04-08 2017-10-12 Phico Therapeutics Ltd Modifying bacteriophage
CN112823206B (zh) * 2018-10-17 2024-04-16 深圳华大生命科学研究院 从细菌全基因组序列中挖掘温和型噬菌体的方法、装置和存储介质
US11724057B2 (en) 2019-12-16 2023-08-15 Melissa H. Egts Protective, sanitary, securable nasal cannula cover
USD942002S1 (en) 2019-12-16 2022-01-25 Melissa H. Egts Nasal cannula cover
DE102024113842A1 (de) * 2024-05-16 2025-11-20 bifa Umweltinstitut GmbH Verfahren zur Verringerung der bakteriellen Last auf bzw. in einer Klimaanlage

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051066A2 (en) 2000-01-11 2001-07-19 Intralytix, Inc. Reduction in bacterial colonization by administering bacteriophage compositions
WO2006066224A2 (en) 2004-12-14 2006-06-22 Yale University Virulence targeted antibiotics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270939B (it) * 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
US6203986B1 (en) * 1998-10-22 2001-03-20 Robert H. Singer Visualization of RNA in living cells
ES2252263T3 (es) * 2000-07-25 2006-05-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Bacteriofago que tiene una gama de hospedadores multiple.
GB0028130D0 (en) * 2000-11-17 2001-01-03 Phico Therapeutics Ltd Polypeptide and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051066A2 (en) 2000-01-11 2001-07-19 Intralytix, Inc. Reduction in bacterial colonization by administering bacteriophage compositions
WO2006066224A2 (en) 2004-12-14 2006-06-22 Yale University Virulence targeted antibiotics

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"PCR Protocols : a guide to methods and applications", 1989, ACADEMIC PRESS
CADWELL, R.C. ET AL.: "Randomizatlon of genes by PCR mutagenesis", PCR METHODS APPL., 1992, pages 28 - 33
MASATOSHI Y. ET AL.: "Alteration of tail fiber protein GP38 enables T2 phage to infect E.coli O157:H7", JOURNAL OF BIOTECHNOLOGY, vol. 115, 2005, pages 101 - 107
MILLER E. S. ET AL: "Select this articleBacteriophage T4 Genome", MICROBIOL MOL. BIOL. REV., vol. 67, no. 1, March 2003 (2003-03-01), pages 86 - 156
SAMBROOK J.; RUSSEL D.W.: "Molecular Cloning, a Laboratory Manual", 2001, CHSL PRESS
THIEL, K., NATURE BLOTECHNOLOGY, vol. 22, 2004, pages 31 - 36

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010125296A1 (fr) 2009-04-30 2010-11-04 Pherecydes Pharma Modification du genome d'un bacteriophage lytique par immobilisation dudit bacteriophage dans sa bacterie hote
FR2945049A1 (fr) * 2009-04-30 2010-11-05 Pherecydes Pharma Modification du genome d'un bacteriophage lytique par immobilisation dudit bacteriophage dans sa bacterie hote
JP2012525135A (ja) * 2009-04-30 2012-10-22 フエルシド・フアルマ 溶菌性バクテリオファージをこの宿主細菌中に固定化することにより該バクテリオファージのゲノムを修飾する方法
US9029153B2 (en) 2009-04-30 2015-05-12 Pherecydes Pharma Modification of the genome of a lytic bacteriophage by immobilizing said bacteriophage in the host bacterium thereof
AU2010243421B2 (en) * 2009-04-30 2017-01-12 Pherecydes Pharma Modification of the genome of a lytic bacteriophage by immobilizing said bacteriophage in the host bacterium thereof

Also Published As

Publication number Publication date
JP2010512774A (ja) 2010-04-30
US9315803B2 (en) 2016-04-19
AU2007346006B2 (en) 2013-08-29
AU2007346006A1 (en) 2008-08-07
WO2008093009A8 (fr) 2009-07-16
CA2673579A1 (fr) 2008-08-07
WO2008093009A3 (fr) 2009-02-12
EP2097516A2 (fr) 2009-09-09
FR2910492A1 (fr) 2008-06-27
US20110027231A1 (en) 2011-02-03
FR2910492B1 (fr) 2013-02-15
CA2673579C (fr) 2019-04-09
EP2653536A1 (fr) 2013-10-23
EP2097516B1 (fr) 2012-11-14

Similar Documents

Publication Publication Date Title
US11186830B2 (en) Tuning bacteriophage host range
EP2097516B1 (fr) Procédé de préparation de bactériophages modifiés par insertion de séquences aléatoires dans les protéines de ciblage desdits bactériophages
JP2010512774A5 (https=)
EP2097524B1 (fr) Procede de diversification aleatoire d'une sequence genetique permettant de preserver l'identite de certains segments internes de ladite sequence genetique
CA2760275C (fr) Modification du genome d'un bacteriophage lytique par immobilisation dudit bacteriophage dans sa bacterie hote
FR2738841A1 (fr) Procede de polymerisation de sequences d'acides nucleiques et ses applications
Imam Development of culture-free methods for selecting host-specific bacteriophages and the characterisation of unusual bacteriophages
Parcey The Role of CRISPR-Mediated Phage Resistance in the Development of Phage-Based Biocontrol for Erwinia amylovora
Halmillawewa Isolation, characterization, and applications of rhizobiophages
Mohammed Elucidating Mechanisms of Mycobacteriophage Butters Prophage-Mediated Defenses
Knapik Genetic analysis of bacteriophages from clinical and environmental samples
Maguin Restriction-Modification and CRISPR-Cas systems: cooperation between innate and adaptive immunity in prokaryotes
Eugene LeClerc Single‐Stranded DNA Phages
Hossain Molecular Interactions between phage and the catfish pathogen Edwardsiella ictaluri and Comparative Genomics of Epidemic strains of Aeromonas hydrophila
Chevallereau Comprehensive study of new virulent bacteriophages: from transcriptomic and mechanistic characterisations towards evolutionary perspectives
藤原亜希子 Characterization and utilization of bacteriophages infecting Ralstonia solanacearum
Liu Parasite adaptations to dynamic hosts: Bordetella-phage and Bordetella-host interactions
Kukkaro Characterization of New viruses from hypersaline environments
Hutinet Homologous recombination in Bacteriophages, less fidelity for more exchanges
Chan Bacteriophages of marine Roseobacter
OWUSU-BINEY et al. GENETIC MATERIAL
WO2006106193A1 (fr) Methode d'obtention de variants solubles ou mieux exprimes d'une proteine d'interet
FR2883885A1 (fr) Recombinaison in vitro circulaire

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2009542133

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2673579

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007872388

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007346006

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07872388

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2007346006

Country of ref document: AU

Date of ref document: 20071218

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12520789

Country of ref document: US

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)